<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00825721</url>
  </required_header>
  <id_info>
    <org_study_id>CK-0105</org_study_id>
    <nct_id>NCT00825721</nct_id>
  </id_info>
  <brief_title>Dose-Ranging Study of an Ophthalamic Solution in Patients With Loss of Visual Function Due to Age-Related Nuclear Cataract</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Single-Masked, Dose-Ranging Study of C-KAD Ophthalmic Solution in Patients With Loss of Visual Function Due to Age-Related Nuclear Cataracts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chakshu Research, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chakshu Research, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of three doses of C-KAD Ophthalmic Solution
      in patients with loss of visual function due to age-related nuclear cataract
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2007</start_date>
  <completion_date type="Anticipated">September 2009</completion_date>
  <primary_completion_date type="Anticipated">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best-corrected visual acuity by ETDRS</measure>
    <time_frame>360 days</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Nuclear Cataract</condition>
  <arm_group>
    <arm_group_label>1.3% (low dose)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2% (medium dose)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2.6% (high dose)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LiquiTears</intervention_name>
    <description>4 drops applied daily for 360 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C-KAD Ophthalmic Solution</intervention_name>
    <description>4 drops applied daily for 360 days</description>
    <arm_group_label>1.3% (low dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C-KAD Ophthalmic Solution</intervention_name>
    <description>4 drops applied daily for 360 days</description>
    <arm_group_label>2% (medium dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C-KAD Ophthalmic Solution</intervention_name>
    <description>4 drops applied daily for 360 days</description>
    <arm_group_label>2.6% (high dose)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of nuclear sclerosis cataract

          -  BCDVA within the range of 20/40 and 20/80

        Exclusion Criteria:

          -  Any other clinical condition in the eye that may compromise vision

          -  Presence or history of glaucoma

          -  Presence or history of diabetes

          -  Use of eyedrops

          -  Use of steroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanduk Ruit, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tilganga Eye Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reeta Gurung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tilganga Eye Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tilganga Eye Center</name>
      <address>
        <city>Kathmandu</city>
        <country>Nepal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Nepal</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2009</study_first_submitted>
  <study_first_submitted_qc>January 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2009</study_first_posted>
  <last_update_submitted>January 20, 2009</last_update_submitted>
  <last_update_submitted_qc>January 20, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2009</last_update_posted>
  <responsible_party>
    <name_title>Watiri Kamau-Kelley /Manager, Clinical &amp; Regulatory Affairs</name_title>
    <organization>Chakshu Reserach, Inc.</organization>
  </responsible_party>
  <keyword>Cataract Study</keyword>
  <keyword>Ophthalmic Study</keyword>
  <keyword>Agerelated cataract</keyword>
  <keyword>Nuclear Cataract</keyword>
  <keyword>Low grade nuclear cataracts</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

